TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05474053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg (Brilique)
Description: compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg (Ticaloguard)
Description: compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
Study: NCT06289595

Intervention type: DEVICE
Intervention: PBM Ortho device
Description: Device emits light for photobiomodulation (light therapy).
Study: NCT05000736

Intervention type: DRUG
Intervention: palbociclib + aromatase inhibitor
Description: palbociclib + aromatase inhibitor therapy

Intervention type: DRUG
Intervention: fulvestrant
Description: fulvestrant monotherapy
Study: NCT06311071

Intervention type: DIAGNOSTIC_TEST
Intervention: calcium score
Description: Calcium score of coronaries obtained fro coronary CT angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary angiography
Description: Invasive coronary angiography from radial artery with contrast injection
Study: NCT05124483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452X
Description: subcutaneous injection of 90 µg AKS-452X

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452X
Description: subcutaneous injection of 90 µg AKS-452X

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452X
Description: subcutaneous injection of 90 µg AKS-452X
Study: NCT05722886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05124483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452X
Description: subcutaneous injection of 90 µg AKS-452X
Study: NCT05722886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with pertuzumab
Description: The initial loading dose of trastuzumab is 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.~The initial loading dose of pertuzumab is 840 mg administered intravenously every 21 days followed thereafter by a maintenance dose of 420 mg.~Participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib in combination with cobimetinib
Description: Participants will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05168462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced noradrenaline use
Description: Reduced noradrenaline by using a lower MAP target
Study: NCT05372042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT Text Messages
Description: CBT skills based text messages delivered 3x per week for four weeks
Study: NCT05078541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor
Description: The Procedure~1. Injection of local subcutaneous and pericapsular anaesthesia~2. Needle radiofrequency ablation under ultrasound guidance~3. Patients should communicate with operating surgeon upon excessive heat or pain~4. The procedure usually lasts 30-45 minutes
Study: NCT04699968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701，Famitinib
Description: SHR -1701, Intravenous ；Famitinib, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: SHR -1701, Intravenous
Study: NCT06164535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor group
Description: 35 T2DM patients will be given DPP-4 I once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor + metformin group
Description: 35 T2DM patients will be given DPP-4 I + metformin once or twice daily
Study: NCT05015582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op lower body forced air warming (32˚C)
Description: lower body forced air warming at ambient (32˚C) for at least 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op lower body forced air warming (32˚C)
Description: lower body forced air warming at ambient (32˚C) for at least 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre op fluids (45˚C)
Description: fluids from warmed cabinet set at 45˚C

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre op fluids (45˚C)
Description: fluids from warmed cabinet set at 45˚C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming intra-operative at ambient (32˚C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming (32˚C)
Description: Use of upper body forced air warming intra-operative at ambient (32˚C)
Study: NCT05259111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospital
Description: Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
Study: NCT06110039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicothoracic Junction Mobilization
Description: The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Thoracic Spine Manipulation:
Description: The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
Study: NCT05015582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op fluids at room temperature
Description: IV fluids at room temperature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra op upper body forced air warming at (32˚C)
Description: upper body forced air warming intra-operative at ambient (32˚C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming at (32˚C)
Description: upper body forced air warming intra-operative at ambient (32˚C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op upper body forced air warming at (42˚C)
Description: upper body forced air warming intra-operative at ambient (42˚C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op lower body forced air warming at (32˚C)
Description: Lower body forced air warming intra-operative at ambient (32˚C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op lower body forced air warming at (42˚C)
Description: Lower body forced air warming intra-operative at ambient (42˚C)
Study: NCT04716738

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analyses and coprological
Description: We will take a blood and stool sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analyses and coprological
Description: We will take a blood and stool sample
Study: NCT05713591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition care model
Description: The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
Study: NCT05760703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSG-0002 Injection
Description: Intravenous infusion
Study: NCT05015582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra op fluid (42˚C)
Description: IV fluids with hotline fluid warmer set at 42˚C
Study: NCT05407831

Intervention type: GENETIC
Intervention: Genetic
Description: Calculate MODY probability

Intervention type: GENETIC
Intervention: Genetic
Description: Calculate MODY probability

Intervention type: BEHAVIORAL
Intervention: Social habits
Description: Alcohol vs Smoking vs Drug use

Intervention type: BEHAVIORAL
Intervention: Social habits
Description: Alcohol vs Smoking vs Drug use

Intervention type: OTHER
Intervention: Perinatal stress
Description: Survey

Intervention type: OTHER
Intervention: Perinatal stress
Description: Survey
Study: NCT05917353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hinex Jelly
Description: 1. Name: Hinex Jelly~2. Dosage form: Semi-solid jelly/ A-114001297-00000-2~3. Dose(s): 300g/pack (per serving)~4. Dosing schedule: one pack (serving) per day~5. Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food.
Study: NCT06196697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Subjects will receive AK104 by intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: Subjects will receive AK112 by intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
Study: NCT05329350

Intervention type: DEVICE
Intervention: muscular ventricular septal defects
Description: intervention cardiology and structural heart disease, including transseptal puncture.
Study: NCT06415474

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lymphocyte Phenotyping Procedure
Description: For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture.
Study: NCT05937516

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nasotracheal intubation with conventionally
Description: Nasotracheal intubation will be applied conventionally to patients in this group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation with angled ETT using guidewire
Description: a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
Study: NCT06127758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses application
Description: The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical training
Description: Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical training
Description: Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
Study: NCT05768997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose Injection
Description: Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa Injection
Description: Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa Injection
Description: Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
Study: NCT06181253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education
Description: The intervention will be an instructional video describing proper walking technique particularly up flights of stairs for patients to do at home. This will be shown at preoperative surgical clinic and will be available for access at home from patient's cell phones. The video is currently in production at BMC. Additionally, text reminders will be sent daily to remind patients to walk at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Description: Participants will be encouraged to compete 140-150 minutes of moderate aerobic exercise per week- achieved by two walking sessions per day 10-11 minutes in length (realistic/achievable goal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Text reminders will be sent daily to remind patients to walk at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants will be encouraged to walk 10,000 steps daily which will be tracked with a pedometer
Study: NCT05603364

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose
Description: Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine feeding
Description: Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
Study: NCT04654910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS Score Explanation
Description: The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
Study: NCT05371366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD closure with the novel occluder (ReAces)
Description: Transcatheter closure atrial septal defect with the novel occluder (ReAces)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASD closure with normal occluder
Description: Transcatheter closure atrial septal defect with normal occluder
Study: NCT05733845

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
Study: NCT06137066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE +200mg ALA
Description: 200mg green coffee extract + 200mg alpha-lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE +400mg ALA
Description: 200mg green coffee extract + 400mg alpha-lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg GCE + 200mg DHB
Description: 200mg green coffee extract + 200mg dihydroberberine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
Study: NCT05243069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo 3D scanning
Study: NCT06329986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAMER Lens Spectacle
Description: Regular daily wear of TAMER lens spectacle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAMER Lens Spectacle
Description: Regular daily wear of TAMER lens spectacle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SV lenses
Description: SV lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SV lenses
Description: SV lenses
Study: NCT05661435

Intervention type: DEVICE
Intervention: RESP Biosensor
Description: The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
Study: NCT05408195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHATBOT use
Description: Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.